Photodynamic Therapy in Treating Patients With Early Esophageal Cancer
Phase 2
Completed
- Conditions
- First Posted Date
- 2003-10-22
- Last Posted Date
- 2011-12-23
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 30
- Registration Number
- NCT00002935
- Locations
- ๐บ๐ธ
Roswell Park Cancer Institute, Buffalo, New York, United States
Oxaliplatin in Treating Patients With Previously Treated Locally Advanced or Metastatic Colorectal Cancer
Not Applicable
Completed
- Conditions
- First Posted Date
- 2003-07-08
- Last Posted Date
- 2011-03-07
- Lead Sponsor
- Roswell Park Cancer Institute
- Registration Number
- NCT00040820
- Locations
- ๐บ๐ธ
Roswell Park Cancer Institute, Buffalo, New York, United States
Photodynamic Therapy With HPPH in Treating Patients With Non-Small Cell Lung Cancer
Phase 1
Completed
- Conditions
- First Posted Date
- 2003-06-25
- Last Posted Date
- 2011-03-07
- Lead Sponsor
- Roswell Park Cancer Institute
- Registration Number
- NCT00025571
- Locations
- ๐บ๐ธ
Roswell Park Cancer Institute, Buffalo, New York, United States
Irinotecan Followed by Fluorouracil in Treating Patients With Advanced Solid Tumors
Phase 1
Completed
- Conditions
- First Posted Date
- 2003-06-20
- Last Posted Date
- 2011-03-07
- Lead Sponsor
- Roswell Park Cancer Institute
- Registration Number
- NCT00024141
- Locations
- ๐บ๐ธ
Roswell Park Cancer Institute, Buffalo, New York, United States
High-Dose Chemotherapy, Total-Body Irradiation, and Autologous Stem Cell Transplantation or Bone Marrow Transplantation in Treating Patients With Hematologic Cancer or Solid Tumors
- First Posted Date
- 2003-05-07
- Last Posted Date
- 2013-05-09
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 451
- Registration Number
- NCT00060255
- Locations
- ๐บ๐ธ
Roswell Park Cancer Institute, Buffalo, New York, United States
Photodynamic Therapy Using HPPH in Treating Patients With Obstructive Esophageal Tumors
Phase 1
Completed
- Conditions
- First Posted Date
- 2003-05-07
- Last Posted Date
- 2011-03-09
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 11
- Registration Number
- NCT00060268
- Locations
- ๐บ๐ธ
Roswell Park Cancer Institute, Buffalo, New York, United States
High Dose Chemotherapy, Peripheral Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Acute Myeloid Leukemia
Phase 3
Completed
- Conditions
- First Posted Date
- 2003-04-16
- Last Posted Date
- 2012-04-13
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 61
- Registration Number
- NCT00002945
- Locations
- ๐บ๐ธ
Roswell Park Cancer Institute, Buffalo, New York, United States
Interleukin-2 and Stem Cell Factor in Treating Patients With AIDS or AIDS-Related Cancer
Phase 1
Completed
- Conditions
- First Posted Date
- 2003-04-09
- Last Posted Date
- 2013-01-31
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 1
- Registration Number
- NCT00058045
- Locations
- ๐บ๐ธ
Arthur G. James Cancer Hospital - Ohio State University, Columbus, Ohio, United States
๐บ๐ธRoswell Park Cancer Institute, Buffalo, New York, United States
Genetic Changes in Patients With Non-Small Cell Lung Cancer Who Are Receiving Vinorelbine and Gemcitabine Before Surgery
Phase 2
Completed
- Conditions
- First Posted Date
- 2003-04-09
- Last Posted Date
- 2011-03-08
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 21
- Registration Number
- NCT00057798
- Locations
- ๐บ๐ธ
Roswell Park Cancer Institute, Buffalo, New York, United States
Compassionate Use of Beclomethasone in Treating Patients With Graft-Versus-Host Disease of the Gastrointestinal Tract
Not Applicable
Completed
- Conditions
- First Posted Date
- 2003-03-07
- Last Posted Date
- 2011-03-08
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 51
- Registration Number
- NCT00055666
- Locations
- ๐บ๐ธ
Roswell Park Cancer Institute, Buffalo, New York, United States
ยฉ Copyright 2024. All Rights Reserved by MedPath